State Key Laboratory of Natural Medicines, Center of Advanced Pharmaceuticals and Biomaterials, School of Pharmacy, China Pharmaceutical University, Nanjing, PR China.
J Cardiovasc Pharmacol. 2022 Sep 1;80(3):407-416. doi: 10.1097/FJC.0000000000001311.
Cardiovascular disease is responsible for the largest number of deaths worldwide, and atherosclerosis is the primary cause. Apoptotic cell accumulation in atherosclerotic plaques leads to necrotic core formation and plaque rupture. Emerging findings show that the progression of atherosclerosis appears to suppress the elimination of apoptotic cells. Mechanistically, the reduced edibility of apoptotic cells, insufficient phagocytic capacity of phagocytes, downregulation of bridging molecules, and dysfunction in the polarization of macrophages lead to impaired efferocytosis in atherosclerotic plaques. This review focuses on the characteristics of efferocytosis in plaques and the therapeutic strategies aimed at promoting efferocytosis in atherosclerosis, which would provide novel insights for the development of antiatherosclerotic drugs based on efferocytosis.
心血管疾病是全球范围内导致死亡人数最多的疾病,而动脉粥样硬化是其主要病因。凋亡细胞在动脉粥样硬化斑块中的积累会导致坏死核心的形成和斑块破裂。新的研究结果表明,动脉粥样硬化的进展似乎抑制了凋亡细胞的清除。从机制上讲,凋亡细胞的吞噬能力降低、吞噬细胞的吞噬能力不足、桥接分子的下调以及巨噬细胞极化功能障碍都会导致动脉粥样硬化斑块中吞噬作用受损。本综述重点介绍了斑块中吞噬作用的特征以及促进动脉粥样硬化中吞噬作用的治疗策略,这将为基于吞噬作用的抗动脉粥样硬化药物的开发提供新的思路。